To this end, we compared the tumor-suppressing activity of TB206-001, pembrolizumab, and AZD4635, a clinical-stage small molecule inhibitor A2AR [11], in HuCD34-NCG mice inoculated with colon adenocarcinoma (COLO 205) cells (Fig 4A). This evidence concerns the gene ADORA2A and colon adenocarcinoma.